Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2021-22 | Page 131

### 31. Other Comprehensive Income - Unrealized Gain/(Loss)

Amount in Taka

| Particulars | Note | July 2021- June 2022 | July 2020- June 2021 |
|---|---|---|---|
| Fair Value Gain/(Loss) on Investment in Listed Shares | | 6,764,517 | 12,840,831 |
| **Total** | | **6,764,517** | **12,840,831** |

### 32. Earnings Per Share (EPS)

| Particulars | Note | July 2021- June 2022 | July 2020- June 2021 |
|---|---|---|---|
| (a) Earnings attributable to the Owners of the Company | | 5,123,136,712 | 5,127,693,711 |
| (b) Weighted average number of Shares outstanding during the year | | 446,112,089 | 446,112,089 |
| **Earnings Per Share (EPS)** | | **11.48** | **11.49** |

### 33. Net Asset Value (NAV) Per Share

Amount in Taka

| Particulars | Note | June 30, 2022 | June 30, 2021 |
|---|---|---|---|
| Total Assets | | 66,148,035,742 | 52,246,084,026 |
| Less Total Liabilities | | (21,512,031,284) | (14,881,219,197) |
| Less Non-controlling Interest | | (4,035,506,641) | (334,306,627) |
| **Equity Attributable to the Owners of the Company** | | **40,600,497,817** | **37,030,558,202** |
| Number of Ordinary Shares | | 446,112,089 | 446,112,089 |
| **Net Asset Value (NAV) Per Share** | | **91.01** | **83.01** |

### 34. Net Operating Cash Flows Per Share (NOCFPS)

Amount in Taka

| Particulars | Note | July 2021- June 2022 | July 2020- June 2021 |
|---|---|---|---|
| Net Cash Generated from Operating Activities | | 5,214,176,450 | 6,023,263,955 |
| Number of Ordinary Shares | | 446,112,089 | 446,112,089 |
| **Net Operating Cash Flows Per Share (NOCFPS)** | | **11.69** | **13.50** |